Introduction
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are high-risk hematologic malignancies, with long-term disease-free survival obtained in only 20-40% of patients. 1, 2 AML occurs at all ages, and outcome is dismal in particular for elderly patients, who generally have more aggressive disease while only a minority qualifies for high-dose chemotherapy. [3] [4] [5] For patients younger than 60 years fit enough to be treated aggressively with chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT) the prognosis is better, with five-year survival rates of 40 -50%. 4 ,5 A significant proportion of allogeneic HSCT recipients dies however as a result of transplantation related complications such as graft versus host disease (GvHD) and infections, while the lives of allogeneic HSCT survivors are often significantly impacted by the detrimental effects of acute and chronic GvHD. 6 Hence, alternative and less harmful treatment approaches that can also be applied to elderly or less-fit younger patients are highly needed.
New modalities such as treatment of AML and MDS with monoclonal antibodies are being explored. In non-myeloid malignancies, antibodies directed against CD20 (rituximab, ofatumumab) and CD38 (daratumumab), antibody-drug conjugates like brentuximab-vedotin (CD30), chimeric antigen receptor (CAR) T cells and chimeric proteins (bispecific T cell engagers (BiTE)) that redirect T cells to CD19 expressing malignant cells have significantly improved the prognosis of patients. [7] [8] [9] [10] [11] [12] [13] [14] In myeloid malignancies, CD33, CD123 (IL3 receptor), CLEC12A/CCL-1 (C-type lectin) and CD25 are being explored as immunotherapeutic targets. [15] [16] [17] [18] However, while for example the antibody-drug conjugate vadastuximab-talirine (SGN-CD33A) was effective and safely applied in combination with hypomethylating agents or cytarabine in small series of patients (Abstract #591, American Society of Hematology, 2016), these myeloid targets are not exclusively expressed by AML/MDS and off-target side effects are a concern. Vadastuximab-talarine and CD33 as a bispecific T cell engager antibody showed significant toxicity and clinical studies with these agents are currently on hold. These observations have made it clear that there is a need for the identification of novel tumor antigens, specific for AML and MDS. The only form of immunotherapy with proven efficacy in AML and MDS so far is allogeneic hematopoietic stem cell transplantation (HSCT). Potent graft versus leukemia (GvL) responses are generated via the induction of T cell, NK cell and antibody responses and are associated with tumor clearance and survival. 19 Targets of GvL antibodies as identified by serologic screening of leukemia derived cDNA libraries or protein micro-arrays include both intracellular and membrane expressed proteins. [20] [21] [22] [23] While these data suggest that antibody responses contribute to the GvL effect of allogeneic HSCT, the antibody producing B cell clones of these patients
were not retrieved in a monoclonal format, and the actual contribution of these antibodies to GvL responses could not be verified. Nevertheless, the ability of the donor immune system to elicit antibodies directed against malignant cells via allogeneic HSCT is important as it can be employed to identify novel tumor antigens, expressed on AML and MDS cells.
Here, we examined the antibody repertoire of an allogeneic HSCT patient with high risk AML who remained disease free due to a potent graft versus leukemia response. We obtained 5 monoclonal antibodies from this patient that bound to AML cells and only weakly or not at all to non-transformed cells. One of these antibodies in particular, AT1413, bound to all AML cell lines and leukemic blasts isolated from newly diagnosed AML and MDS patients tested.
The target of this antibody is a sialylated epitope on CD43 (CD43s), which is overexpressed by malignant myeloid cells. AT1413 induced antibody dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) on AML cells in vitro and in vivo without affecting non-malignant cells.
Materials and methods

Patient and healthy human materials
Study protocols were approved by the Medical Ethical Committee of the Academic Medical
Centre. All participants signed informed consent. Freshly isolated blasts were obtained from blood or bone marrow of AML/MDS patients. Healthy bone marrow was acquired from the sternum of patients undergoing thoracotomy for cardiac surgery. Healthy PBMCs were isolated from buffy coats from blood donations (Sanquin, the Netherlands).
Cells and cell lines
The following cells and cell lines were used: THP-1, HL-60, HepG2, Huh7, CaCo-2, DLD- Jefferson. 24 Cells were maintained according to manufacturer's instructions. All culture medium was acquired from Gibco or Lonza, the penicillin/streptomycin was obtained from Roche and the FBS from Hyclone. All cultures were routinely tested for the presence of mycoplasma by PCR.
B cell cloning, antibody selection and recombinant antibody production
Memory CD27+ IgG+ B cells were sorted and transduced as described previously using a FACS ARIA3 from BD, 25 . The in-house generated influenza-specific antibody AT1002 (AT10-002) 26 was used as a negative control. To produce recombinant antibody we isolated total RNA with the RNeasy® mini kit (Qiagen), generated cDNA, performed PCR and cloned the heavy and light chain variable regions into the pCR2.1 TA cloning vector (Invitrogen). Several independent cloning experiments were performed to rule out reverse transcriptase or DNA polymerase induced mutations. Heavy and light variable regions of each antibody were cloned in frame with human IgG1 and Kappa constant regions into a pcDNA3.1 (Invitrogen) based vector and transiently transfected 293T cells; recombinant antibodies were purified from the culture supernatant with Protein A columns.
AT1413 target identification and validation
THP-1 lysate (0,5% Triton X114 (Sigma), 150mM NaCl, 10mM Tris-HCL pH7.4, 1,5mM MgCl2 plus protease and phosphatase inhibitors (Roche)) was precleared with palivizumab (antibody against RSV-F), Protein-G and Streptavidin beads (Pierce) and incubated with bead-bound AT1413 or control antibody AT1002 (3 hrs at 4°C). After washing, proteins were eluted from the beads (0,1M Glycine pH10,5, 150mM NaCl, 1% Triton X100, 1mM EDTA), run on an SDS-PAGE gel and incubated with Imperial protein stain (Pierce). Some IP samples were transferred to PVDF membrane (Bio-RAD) for immunoblotting with Ponseau S, blocked with BSA and incubated with CD43 (clone MEM-59, Abcam) for Western blot analysis.
Trypsin digestion and mass spectrometry analysis
Protein bands were digested overnight with trypsin (12.5 ng/μl in 25 mM NH4HCO3, Sequencing grade modified trypsin, Promega) after reduction and alkylation with dithiothreitol (10 mM) and iodoacetamide (55 mM), respectively. Tryptic peptides were analyzed by LC-MS/MS analysis using an Ultimate 3000 RSLCnano system (Thermo Fisher Scientific) coupled to an amaZon ETD ion trap (Bruker Daltonics). Proteins were subsequently identified by searching the mass spectrometry data against the human Uniprot database using the Mascot algorithm 
Generation of CD43 truncated variants
CD43 cDNA (Geneart, Life Technologies) with a 3xFLAG tag in-frame on either C-or N-terminus was cloned into the pHEF-TIG third-generation lentiviral vector containing an IRES-GFP 3' of the CD43 cDNA; VSV-G lentiviral particles were produced in HEK293T cells. THP1, MOLM and other cells were transduced with these viruses in the presence of retronectin and sorted for GFP expression to obtain a pure population of CD43 overexpressing cells. Truncated CD43 variants were constructed by PCR-cloning of the CD43 C-terminal FLAG-tagged cDNA to contain the signal peptide (AA 1-19) followed by the wild-type full length extracellular sequence (variant A: S20-P400, followed by 3xFLAG: DYKDHDGDYKDHDIDYKDDDDK) or truncated extracellular sequences (variant B-J). B: 31-400; C: 59-400; D: 82-400; E: 112-400; F: 133-400; G: 148-400;
H: 166-400; I: 184-400; J: 202-400; K: 220-400. These variants were expressed in THP1 cells by lentiviral transduction and sorted for GFP expression. Sorted cells were lysed and immunoprecipitated with AT1413 and control CD43 antibodies as described above. Eluted IP samples were run on SDS-PAGE and immunoblotted with anti-FLAG-HRP (Sigma). 
Flow cytometry analyses
Results
Identification of AML specific B cell clones
We selected a 49-year old patient with relapsed acute monoblastic leukemia (AML-NOS; patient 101), who has remained disease free for more than 6 years after receiving a non- Figure S1 ). By subcloning (1 cell/well) of these mini-cultures we retrieved five clonal B cell lines that produced antibodies binding to AML cell lines ( Table 1) .
Two of these antibodies, AT1413 and AT1508, had an IgG1 isotype and more than 10 somatic hypermutations in the heavy and light chains indicating antigen-induced class-switching and affinity maturation. Using micro-chimerism analysis of genomic polymorphisms through profiling of the short tandem repeat (STR) DNA loci of the parental B cell clone we confirmed that all antibodies were of donor-origin. classification AML types ( Figure 1A ). The antibody also bound to a subset of non-malignant CD34+ and CD38+ hematopoietic progenitor cells obtained from healthy bone marrow, to peripheral blood monocytes and granulocytes derived from healthy individuals ( Figure 1B Figure 1B and Figure S2 ). We performed a tissue micro-array (TMA) immunohistochemistry (IHC) screen on a large variety of healthy tissues (177 tissue cores including amongst others the small and large intestines, muscle, kidney, liver, gallbladder, pancreas, lung). Membrane staining of a few mononuclear cells in tonsils was confirmed. We observed scattered intracellular staining of macrophage-type cells throughout the tissues, most prominently in the liver (Kuppfer cells), and we noted staining of endothelial cells in blood vessels ( Figure 1C ). FACS analysis of AT1413
binding to the endothelial cell lines HUVEC and HAEC demonstrated that this occurred only at relatively high antibody concentrations ( Figure 1D ). In the same experiment we observed binding of AT1413 to granulocytes to be much weaker than to AML cells. AT1413 also bound to a subset of non-malignant hematopoietic progenitor cells and to peripheral blood derived non-malignant monocytes and granulocytes. AT1413 did not bind to to blood, tonsil or thymus derived mature and immature lymphoid cells, nor did it bind to the tissue cell lines HepG2 (liver), Huh7 (liver), H69 (cholangiocytes), Caco2 (colon), or BJ (foreskin fibroblasts), and primary cultured fibroblasts (NHDF-Ad-Der). The in-house generated influenza-specific antibody AT1002 was used as a negative control in A -C.
The target of AT1413 is a novel sialylated CD43 epitope (CD43s)
Immunoprecipitation ( We confirmed CD43 as the target protein of AT1413 by western blot analysis using Mem59, a commercially available CD43 antibody ( Figure 2B ).
CD43 is a highly O-glycosylated protein, 28 and the commercially available CD43 antibodies Mem59, DF-T1 and 84-3C1 bind to sialylated epitopes of CD43. [29] [30] [31] Removing all α2-3-N-acetylneuramic acids (sialic acids) from THP-1 cells by pre-incubating the cells with neuraminidase abrogated binding of all antibodies, except L10 (that is directed against the same peptide as 84-3C1 but binds a non-sialylated epitope 31 ), in a dose-dependent manner ( Figure 2C ). Thus, AT1413 targets an epitope that is sialylated, like the epitopes recognized by most commercially available CD43 antibodies. However, whereas AT1413 and the commercially available CD43
antibodies bound THP-1 cells, AT1413 did not bind the T ALL cell line Jurkat, in contrast to the other CD43 antibodies ( Figure 2D ). In addition, none of the commercially available CD43
antibodies competed with binding of AT1413 to THP-1 cells ( Figure 2E ), whereas they could inhibit binding of each other, as described previously. 31 Together these data indicate that AT1413 recognized a unique epitope that is not targeted by other CD43 antibodies.
To more specifically identify the binding epitope of AT1413, we generated 10 FLAG-tagged truncated variants of CD43 that were expressed in THP1 cells ( Figure Competition experiment with AT1413 and commercially available CD43 specific antibodies. THP-1 cells were incubated with indicated antibodies, biotinylated AT1413 and streptavidin PECy7. AT1413 binding to THP-1 target cells was not affected by pre-incubation of the cells with commercially available CD43 antibodies, but was inhibited in a dose-dependent manner when THP-1 cells were pre-incubated with unlabeled AT1413. 
CD43s is overexpressed on AML and MDS patient derived leukemic blasts
Thus, AT1413 is an antibody that targets a unique, sialylated epitope on CD43 that is expressed on malignant myeloid cell lines. To further evaluate the breadth and specificity of AT1413, we tested binding of this antibody to bone marrow and peripheral blood samples obtained from patients with AML and MDS. The first patient to be tested was patient 101, the allogeneic HSCT recipient of whom AT1413 was obtained. Viable AML blasts of this patient had been frozen and stored at diagnosis and AT1413 showed clear binding to these leukemic blasts. (Figure 3A) . We then tested binding of AT1413 to leukemic blasts obtained from 60 randomly selected, newly diagnosed patients with MDS and AML, and found that AT1413 bound to all samples tested ( Figure 3B ; Table 2 ). All WHO 2008 AML subtypes 32 were represented in this patient cohort (although due to the relatively small sample size not in the same proportions as published 33 ),
including patients with high-risk MDS and patients with extramedullary AML (myeloid sarcoma, Figure 3C ). Interestingly, in a patient diagnosed with therapy-related AML several years after intensive chemotherapy for multiple myeloma, AT1413 clearly distinguished myeloid leukemic blasts from multiple myeloma cells ( Figure 3D ). In a direct comparison with bone marrow obtained from six newly diagnosed patients with AML we confirmed that binding of AT1413 to leukemic blasts was stronger than binding to non-leukemic granulocytes, monocytes and lymphocytes of the same patient ( Figure 3E ). Representative examples of AT1413 binding to AML blasts obtained from newly diagnosed patients with AML or MDS (see also AT1413 binding to extramedullary AML of 2 patients (myeloid sarcoma (chloroma) of inguinal node (1) and skin (2)). Paraffin embedded THP-1 and Jurkat cells were used as a positive and negative control, respectively. MFI fold increase (FI) for AT1413 binding to CD45dim leukemic blasts isolated from newly diagnosed AML and MDS patients. Depicted is MFI for AT1413 divided by the MFI of the negative control antibody (AT1002). *Patient deferred further treatment and cytogenetic and molecular analyses were not performed; **from this patient AT1413 was retrieved.
AT1413 induces ADCC and CDC of AML blasts but not non-malignant cells in vitro
We then tested the in vitro capacity of this antibody to induce target cell killing by antibody dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC), as described previously. 34 Incubation of the AML cell line SH2 with AT1413 and human peripheral blood mononuclear cells (PBMC) or rabbit complement induced ADCC and CDC, respectively ( Figure 4A ). Endothelial cells (HAEC or HUVEC) and granulocytes, that bound AT1413 albeit to a lesser extent than AML cells, were not killed when incubated with AT1413 and PBMC ( Figure   4B ). Moreover, when we incubated SH2 cells with AT1413 and whole blood from a healthy individual, SH2 cells were killed but healthy peripheral blood polymorphonuclear cells (PMN)
were not affected ( Figure 4C ). 
AT1413 specifically eliminates human AML blasts in vivo
To test whether AT1413 affects tumor growth in vivo, we set up a mouse model for human 
Blood
Bioluminescence of individual organs harvested after mice were sacrificed. 
Discussion
The development novel forms of immunotherapy -other than allogeneic HSCT -for the treatment of AML would be a significant therapeutic advance. In search for novel AML/MDS specific antigens that can be employed as targets for immunotherapy we screened the B cell repertoire of a patient with a durable remission after receiving an allogeneic HSCT for relapsed AML, for antibodies that react with cell surface antigens expressed on AML cells. We isolated 5 B cell clones producing such antibodies and one of these antibodies, AT1413, recognized a novel sialylated epitope on CD43 (CD43s). CD43 is a heavily O-glycosylated mucin-like type I transmembrane protein that is present on the surface of most hematopoietic cells including hematopoietic stem cells, but not on resting B cells and erythrocytes. 35 Different CD43
glycoforms that can be co-expressed on one cell have been described, each with specific functions including roles in activation, proliferation, migration and apoptosis. 36 While in healthy individuals CD43 is exclusively expressed on hematopoietic cells, certain CD43 glycoforms are expressed by a number of non-hematologic tumors, including colon, lung and breast carcinoma, where it affects growth, migration, metastasis and interaction with the immune system, and hence prognosis. 28 For example the UN1/CD43 epitope is a specific CD43 glycoform expressed by T lymphocytes, thymocytes and certain leukemic T cell lines, and by certain solid tumor types. 37, 38 We identified CD43s, a novel CD43 glycoform that is overexpressed on AML cell lines and blasts of AML patients. In fact, while the extent of expression is variable, CD43s is expressed on all cells may raise safety concerns, however, the binding is weak and AT1413 does not mediate ADCC or CDC against endothelial cells. In this respect it is noteworthy that trastuzumab, a HER2/neu specific antibody that is widely used in the treatment of HER2/neu over-expres-sing breast cancer interacts with cardiac endothelial cells but is safely applied in humans. 39 Another important point with respect to safety is that although AT1413 is a highly mutated, antigen-experienced antibody, the patient of whom this antibody was derived did not experience vascular complications, cardiac issues, neutropenia or pancytopenia after allogeneic HSCT. He did develop bronchiolitis obliterans syndrome and pulmonary dysfunction after syncytial respiratory (RS) virus infection, but is no longer on immunosuppressants.
In conclusion, we identified CD43s Transient weight loss of mice treated with AT1413. Weight was set at 100% at the start of treatment (day 19 after AML inoculation).
Supplemental Figure 8
Supplemental Figure 8 AT1413 treatment of non--humanized NSG mouse with AML AT1413 treatment of non-humanized NSG mice with human AML. Female non-humanized NSG mice were inoculated with 10 7 luciferase labeled SH2 cells via tail vein injection. Mice were treated with the AML antibody AT1413 or with an influenza specific antibody (AT1002) twice a week, from day 19 to day 35.
